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Abstract
The sympathetic nervous system (SNS) plays an important role in mediating bone remodeling. However, the exact role that
beta-1 adrenergic receptors (beta1AR) have in this process has not been elucidated. We have previously demonstrated the
ability of dobutamine (DOB), primarily a beta1AR agonist, to inhibit reductions in cancellous bone formation and mitigate
disuse-induced loss of bone mass. The purpose of this study was to characterize the independent and combined effects of
DOB and hindlimb unloading (HU) on cancellous bone microarchitecture, tissue-level bone cell activity, and osteocyte
apoptosis. Male Sprague-Dawley rats, aged 6-mos, were assigned to either normal cage activity (CC) or HU (n = 18/group)
for 28 days. Animals were administered either daily DOB (4 mg/kg BW/d) or an equal volume of saline (VEH) (n = 9/gp).
Unloading resulted in significantly lower distal femur cancellous BV/TV (233%), Tb.Th (211%), and Tb.N (225%) compared
to ambulatory controls (CC-VEH). DOB treatment during HU attenuated these changes in cancellous bone microarchitecture,
resulting in greater BV/TV (+29%), Tb.Th (+7%), and Tb.N (+21%) vs. HU-VEH. Distal femur cancellous vBMD (+11%) and total
BMC (+8%) were significantly greater in DOB- vs. VEH-treated unloaded rats. Administration of DOB during HU resulted in
significantly greater osteoid surface (+158%) and osteoblast surface (+110%) vs. HU-VEH group. Furthermore, Oc.S/BS was
significantly greater in HU-DOB (+55%) vs. CC-DOB group. DOB treatment during unloading fully restored bone formation,
resulting in significantly greater bone formation rate (+200%) than in HU-VEH rats. HU resulted in an increased percentage
of apoptotic cancellous osteocytes (+85%), reduced osteocyte number (216%), lower percentage of occupied osteocytic
lacunae (230%) as compared to CC-VEH, these parameters were all normalized with DOB treatment. Altogether, these data
indicate that beta1AR agonist treatment during disuse mitigates negative changes in cancellous bone microarchitecture
and inhibits increases in osteocyte apoptosis.
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Introduction
Osteoporosis is a debilitating skeletal disorder reportedly
affecting nearly 44 million in the United States alone [1]. Fragility
fractures common in those with advanced osteoporosis can result
in a reduced quality of life [2,3,4,5]. Recently, it has been
estimated that the cost associated with treating new osteoporotic
fractures in the US will total $16.9 billion [6]. Furthermore, a
significant number of osteoporotic patients are bedridden,
resulting in greater risk for debilitating secondary physiological
effects and even death [7].
Similar to the effects of prolonged bed rest in humans, rodent
hindlimb unloading (HU) significantly reduces cancellous bone
mass and leads to deleterious changes in microarchitecture due to
early increases in bone resorption followed by prolonged
depressions in bone formation [8,9,10,11]. Unloading-associated
reductions in metaphyseal bone mass are associated with increased
osteocyte and osteoblast apoptosis. Dramatic increases are
observed in the number of apoptotic osteocytes in cancellous
bone as early as 3 days after initiation of HU [12,13].
Isoproterenol, a beta-adrenergic receptor agonist (betaAR)
(equally stimulating beta-1 and beta-2 adrenergic receptors), has
been found to have anti-apoptotic effects on cultured osteoblasts
[14]. Taken together, these data suggest that reducing osteocyte/
osteoblast apoptosis during the early stages of unloading may be
an effective strategy to preserve cancellous bone mass and
maintain osteoblast function.
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Although stimulation of the SNS has been documented to
increase bone resorption, resulting in reduced cancellous bone
mass and microarchitecture, this has been primarily attributed to
stimulation of beta-2 adrenergic receptors (beta2AR)
[15,16,17,18]. However, the exact role that beta-1 adrenergic
receptors (beta1AR) have in this process has not been elucidated.
Dobutamine (DOB), primarily an beta1AR agonist, significantly
blunts HU-induced reductions in cortical bone area and cross-
sectional moment of inertia (CSMI), as well as mitigating the
decreases in femoral mid-diaphyseal cortical bone formation [19].
Furthermore, we have previously demonstrated the ability of DOB
to inhibit reductions in cancellous bone formation and mitigate
losses in bone mass at the proximal tibia and femoral neck [20].
The data presented in the current paper derive from a similar but
separate protocol and demonstrate a direct relationship between
alterations in osteoblast activity, osteocyte apoptosis, and cancel-
lous microarchitecture resulting from beta1AR agonist treatment
during hindlimb unloading. These results provide useful insight
into underlying mechanisms involved in disuse-induced bone loss.
Hence, the purpose of the current project was to extend our
previous findings and characterize the independent and combined
effects of DOB and hindlimb unloading on cancellous bone
microarchitecture, osteoblast activity, and osteocyte apoptosis. We
hypothesized that unloading would increase osteocyte apoptosis in
animals experiencing metaphyseal bone loss and that DOB
administered during 28-day HU would mitigate deleterious




All research was conducted in a facility accredited by the
Association for the Assessment and Accreditation of Laboratory
Animal Care (AAALAC). All procedures involving animals were
reviewed and approved by the Texas A&M University Institu-
tional Animal Care and Use Committee. At the end of the study,
animals were anesthetized with a ketamine-xylazine cocktail
(ketamine 50 mg/kg, medetomidine 0.5 mg/kg) and subsequently
euthanized by decapitation, in accordance with the recommen-
dations and guidelines of the American Veterinary Medical
Association.
Animals and Experimental Design
Thirty-six male Sprague-Dawley rats were obtained from
Harlan (Houston, TX) at 6 months of age and allowed to
acclimate to their surroundings for 14 days prior to initiation of the
study. All animals were housed in a temperature-controlled
(2362uC) room with a 12-hour light-dark cycle in an AAALAC-
accredited animal care facility and were provided standard rodent
chow (Harlan Teklad 8604) and water ad-libitum.
All animals were randomly assigned to one of two activity
groups according to body mass on day -1: normal ambulatory cage
activity (CC; n= 18) or hindlimb unloading (HU; n= 18) for 28
days. Each activity group was further divided by random
assignment to receive daily intraperitoneal (IP) injections of
dobutamine (DOB; 4 mg/kg body mass n= 9) or an equal volume
of saline solution (VEH; n= 9). We previously demonstrated that
this dose of DOB effectively mitigated disuse-induced reductions in
proximal tibia total vBMD during 28-day HU [20]. Dobutamine
hydrochloride solution (Sigma-Aldrich Corp.) was made fresh
daily and stored, along with saline solution, at 4uC until usage.
Hindlimb Unloading
Hindlimb unloading was achieved by tail suspension as
previously described [10,21]. Briefly, while the rat was under
anesthesia, the tail was cleaned and dried thoroughly. A thin layer
of adhesive (Amazing Goop, Eclectic Products, LA) was applied to
the proximal half of the tail along the medial and lateral sides. A
standard porous tape (Kendall, Mansfield, MA) harness was
pressed firmly to the glue and allowed to dry (,30 min). A paper
clip was used to attach the animal’s tail harness to a swivel
apparatus on the wire spanning the top of an 18’’618’’618’’ cage.
Calcein injections (25 mg/kg body mass) were given subcuta-
neously 9 and 2 days prior to euthanasia to label mineralizing
bone for histomorphometric analyses. HU animals were anesthe-
tized before removal from tail suspension at the end of the study to
prevent any weight bearing by the hindlimbs. At necropsy, left
femora were removed, cleaned of soft tissue, and stored at 4uC in
70% ethanol for ex vivo mCT and pQCT scans and subsequent
histomorphometry. Distal right femora were stored in parafor-
maldehyde for paraffin embedding.
Ex Vivo Micro Computed Tomography (mCT)
Microarchitecture of cancellous bone located in the distal left
femur was determined using a Skyscan 1172 high-resolution desk-
top micro-computed tomography system. Bones were wrapped in
parafilm to prevent drying during the scanning. Scans were
obtained using an x-ray source set at 60 kV and 167 mA over an
angular range of 180 degrees (rotational steps of 0.70 degrees) with
a 12 mm pixel size. Projection images were reconstructed using
standard Skyscan software. The trabecular bone compartment was
segmented from the cortical shell for 50 slices in a region
,0.5 mm above the most proximal portion of the growth plate for
each animal. Outcomes variables include cancellous bone
volume/tissue volume (BV/TV, %), trabecular number (Tb.N,
mm21), and trabecular thickness (Tb.Th, mm).
Ex Vivo Peripheral Quantitative Computed Tomography
(pQCT)
Scans were performed ex vivo at the distal metaphysis of the left
femur with a Stratec XCT Research-M device (Norland Corp.,
Fort Atkinson, WI), using a voxel size of 70 mm and a scanning
beam thickness of 500 mm. Daily calibration of this machine was
performed with a hydroxyapatitie standard cone phantom.
Femora were placed in a 70% ethanol filled vial during the
course of the scan. Transverse images of the right femur were
taken at 4.5, 5.0, 5.5, and 6.0 mm from the distal femur plateau. A
standardized analysis for metaphyseal bone (contour mode 3, peel
mode 2, outer threshold of 0.214 g/cm3, inner threshold of
0.605 g/cm3) was applied to each section. Values of total and
cancellous volumetric bone mineral density (vBMD), total bone
mineral content (BMC) and total bone area were averaged across
the three slices to yield a mean value for each animal.
Histomorphometry Analysis
Undemineralized distal left femur were subjected to serial
dehydration and embedded in methylmethacrylate (Aldrich M5,
590-9). Serial frontal sections were cut 8 mm thick and left
unstained for fluorochrome label measurements. Additionally,
4 mm thick sections treated with von Kossa staining were used for
measurement of cancellous bone volume normalized to tissue
volume (BV/TV), and osteoid (Os/BS), osteoblast (ObS/BS), and
osteoclast (OcS/BS) surfaces as a percent of total cancellous
surface. Osteoclasts were conservatively defined as cells adhering
to the bone surface with at least 2 nuclei and a foamy cytoplasm (as
b-1 Agonist Inhibition of Osteocyte Apoptosis during Disuse
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determined from tetrachrome counterstain). Adipocyte density was
calculated as number of adipocytes (Ad.N) divided by the marrow
area (Ma.Ar) of the region of measurement. The histomorpho-
metric analyses were performed by using the OsteoMeasure
Analysis System, Version 1.3 (OsteoMetrics, Atlanta, GA). A
defined region of interest was established ,1 mm from the growth
plate and within the endocortical edges encompassing 829 mm2
at 640 magnification. Total bone surface (BS), single labeled
surface (sLS), double-labeled surface (dLS), interlabel distances,
bone volume, and osteoid/osteoclast/osteoblast surfaces were
measured at6200 magnification. Mineral apposition rate (MAR,
mm/day) was calculated by dividing the average interlabel width
by the time between labels (7 days), and mineralizing surface (MS)
for cancellous bone surfaces (BS) was calculated by using the
formula %MS/BS = {[(sLS/2) + dLS]/BS} X 100. Bone
formation rate (BFR) was calculated as (MAR x MS/BS). All
nomenclature for cancellous histomorphometry follows standard
usage [22].
Osteocyte Apoptosis and Occupied Lacunae
In situ osteocyte apoptosis was assessed from distal femur
sections as previously described [23]. In brief, distal left femurs
were decalcified and subsequently embedded in paraffin, and
serial frontal sections were cut 8 mm thick and mounted on slides.
Apoptosis of osteocytes was detected by in situ terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
using the DNA fragmentation TdT enzyme and fluorescein-dUTP
label (Roche Diagnostics Corp., Indianapolis, IN, USA) in distal
femoral sections counterstained with hematoxylin QS (Vector
Laboratories). Osteocytes residing in trabeculae within an 82
9 mm2 region of interest 1 mm distal to the growth plate were
quantified using the OsteoMeasure Analysis System, Version 1.3
(OsteoMetrics). The total number of osteocytes (N.Ot) within the
region was first counted (under normal light), followed by
identification of TUNEL+ osteocytes using ultraviolet light at
6200 magnification. The percentage of apoptotic osteocytes was
calculated as (TUNEL+ Ot/total N.Ot)6 100. The total number
of lacunae within this same region of interest was also quantified
(under normal light) to determine the total number of osteocytic
lacunae (N.Ot/B.Ar) and osteocyte occupancy frequency (%; total
N.Ot/total # lacunae).
Statistical Analyses
All data were expressed as means 6 SEM, and their statistical
relationships were evaluated using the statistical package SPSS
(v.15) and were analyzed using a two-factor ANOVA (drug and
gravity). When a significant main effect was found, Tukey’s post-
hoc analyses were performed for pairwise comparisons. For all
data, statistical significance was accepted at p#0.05.
Results
Dobutamine administration attenuates early reductions
in body mass associated with disuse
Hindlimb unloading resulted in early reductions in body mass
by Day 7 (29% vs. Day 0), which continued through Day 21 (2
5% vs. Day 0; Fig. 1) and recovered to baseline levels by Day 28.
Although DOB treatment during unloading did not inhibit early
losses in body mass (Day 7/14: 27% vs. Day 0), it did attenuate
this reduction (+4% vs. HU-VEH). Furthermore, recovery of total
body mass in HU-DOB animals occurred by Day 21 and
continued through Day 28. Both groups of cage controls similarly
gained body mass over the experimental period with no difference
between treatments.
Reductions in metaphyseal bone microarchitecture and
mass during unloading are mitigated with DOB
treatment
To assess changes in cancellous bone microarchitecture, ex vivo
mCT scans were performed on the distal femur. Unloading
resulted in significantly lower BV/TV (233%), Tb.Th (211%),
and Tb.N (225%) compared to ambulatory controls (CC-VEH)
(Table 1, Fig. 2). DOB treatment during disuse attenuated these
differences in cancellous bone microarchitecture. BV/TV (+29%),
Tb.Th (+7%), and Tb.N (+21%) were significantly greater in
DOB-treated vs. VEH-treated animals subjected to disuse. There
was no effect of DOB treatment on trabecular bone micro-
architecture in weightbearing control rats.
Hindlimb unloading resulted in significantly lower total BMC
(217%) and vBMD (211%) and cancellous vBMD (225%) as
compared to ambulatory controls (CC-VEH; Table 2). DOB
administration during disuse mitigated reductions in two of these
parameters, resulting in greater total BMC (+8%) cancellous
vBMD (+11%) compared to VEH-treated animals subjected to
disuse (HU-VEH). There was no effect of either unloading or
DOB on proximal tibia bone area. DOB administration did not
significantly alter any parameters in weightbearing cage control
animals.
Dobutamine administration during disuse inhibits
reductions in bone formation by maintaining osteoblast
surface
Hindlimb unloading induced significantly lower OS/BS (2
66%) and Ob.S/BS (249%), and greater Oc.S/BS (+75%) and
adipocyte density (+81%) within bone marrow as compared to
ambulatory controls (Fig. 3, 4). DOB treatment during HU
resulted in significantly greater OS/BS (+158%) and Ob.S/BS (+
110%), and reduced adipocyte density (232%) vs. VEH-treated
animals subjected to HU. Furthermore, Oc.S/BS was significantly
greater in HU-DOB (+55%) vs. CC-DOB group (Fig. 3C). DOB
administration did not affect any of these parameters in
weightbearing cage controls.
Hindlimb unloading resulted in lower MS/BS (252%), MAR
(230%), and cancellous BFR (267%) as compared to ambulatory
Figure 1. Effects of dobutamine (DOB) or vehicle (VEH)
administration during hindlimb unloading (HU) or ambulatory
cage activity (CC) on body mass. * vs. Day 0 (p#0.05); aHU+DOB vs.
HU+VEH (p#0.05); bHU+VEH vs. CC+VEH (p#0.05); cHU+DOB vs. CC+
DOB (p#0.05).
doi:10.1371/journal.pone.0106904.g001
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controls (Fig. 4, 5). DOB treatment during unloading resulted in
significantly greater MS/BS (+140%), MAR (+55%), and BFR (+
200%) than in vehicle-treated unloaded rats (HU-VEH). DOB
administration did not affect dynamic histomorphometry measures
of bone formation activity in weightbearing cage controls.
Increased osteocyte apoptosis and reduced osteocytic
lacunae evidenced during rodent hindlimb unloading is
abolished with dobutamine treatment
In situ nick-end labeling was used to determine the prevalence
of osteocyte apoptosis within distal femur cancellous bone in
rodents subjected to HU and/or beta1AR agonist treatment.
Unloading resulted in a significantly greater percentage of
apoptotic cancellous osteocytes (+85%) as compared to ambula-
tory controls (Fig. 6A). DOB-treatment during disuse prevented
this increase in osteocyte apoptosis, which was 36% lower than in
vehicle-treated rats. There was no difference in osteocyte apoptosis
between the ambulatory control groups.
Hindlimb unloading resulted in reduced osteocyte number (2
16%) and frequency (230%) compared to CC-VEH animals
(Fig. 6 B–C). Animals treated with DOB during disuse mitigated
these reductions, resulting in an increased number of cancellous
bone osteocytes per bone area (+9%) and percent of occupied
osteocytic lacunae (+21%) compared to VEH-treated HU rats.
Discussion
Our data confirm that dobutamine treatment during unloading
inhibited reductions in cancellous bone formation, resulting in
protection of cancellous bone mineral density (vBMD) and bone
volume (BV/TV). Furthermore, dobutamine treatment prevented
increased cancellous osteocyte apoptosis during disuse. We found
no effect of DOB treatment on any of these outcomes when it was
administered to rats experiencing normal ambulatory cage
activity. Taken together, these data demonstrate the dynamic role
that beta-1 adrenergic agonist signaling has on maintaining
cancellous bone during periods of reduced weightbearing or
unloading.
Data from this experiment demonstrate higher forming and
similar resorbing surfaces with dobutamine treatment during
unloading relative to unloading controls. DOB administration
resulted in significantly greater osteoblast (+110%) and osteoid
(2.6-fold) surface within cancellous bone of the distal femur as
compared to vehicle-treated hindlimb unloaded rodents (Fig. 3,
4). Most strikingly, these increases in osteoblast surface were
accompanied by 140% to 200% greater mineralizing surface and
bone formation rate (Fig. 4, 5) and 55% greater mineral
apposition rate vs. HU-VEH group. Additionally, dobutamine
treatment during unloading resulted in significantly greater
osteoclast surface (+110%) compared to vehicle treated ambula-
tory controls (Fig. 3). These data indicate that specific stimulation
of b-1 adrenoreceptors in the setting of disuse is altering
remodeling through a mechanism of stimulating both osteoclasts
and osteoblast activity, but affecting osteoblast activity (MAR)
enough to maintain bone balance and therefore mitigate
reductions in bone mass.
Previous work has demonstrated that salbutamol, a b-2
adrenoreceptor agonist, administered to OVX rodents did not
significantly alter osteoblast or osteoclast activity as compared to
untreated estrogen deficient rats [18]. However, salbutamol-
treated OVX animals significantly increased both active bone
resorbing and forming surfaces as compared to sham-controls.
Mice administered isoproterenol (equally stimulating b-1 and b-2
adrenergic receptors) during unloading exhibit significant reduc-
tions in cancellous BV/TV, attributable to significantly lowered
bone formation [24]. Numerous investigations have demonstrated
that beta2AR agonist administration in weightbearing rats reduces
net bone formation by inhibiting osteoblast and increasing
osteoclast differentiation. Takeda et al. [25] showed that
isoproterenol, a non-specific b-adrenergic agonist, decreased
cancellous BV/TV by significantly reducing osteoblast number
and bone formation rate (224–42% vs. controls). Furthermore,
salbutamol treatment induced significant reductions in both tibia
and femur cancellous bone volume as a consequence of
significantly increased osteoclast surface [15]. Deletion of all
adrenergic receptors in skeletally mature mice results in even
Figure 2. Representative three-dimensional mCT images of the distal femur metaphysis cancellous bone in dobutamine- (DOB) or
vehicle- (VEH) treated rodents during hindlimb unloading (HU) or ambulatory cage activity (CC).
doi:10.1371/journal.pone.0106904.g002
Table 1. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb unloading (HU) or ambulatory cage activity
(CC) on distal femur cancellous bone microarchitecture and structure as measured by ex vivo microCT scans.
CC HU
VEH DOB VEH DOB
BV/TV (%) 20.2361.36 21.0561.24 13.4660.74b 17.4260.96a,c
Tb.Th (mm) 93.1062.09 96.0461.39 83.3661.95b 89.0861.91a,c
Tb.N (mm21) 2.1660.12 2.1960.11 1.6160.08b 1.9560.09a
aHU+DOB vs. HU+VEH (p#0.05); bHU+VEH vs. CC+VEH (p#0.05); cHU+DOB vs. CC+DOB (p#0.05).
doi:10.1371/journal.pone.0106904.t001
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greater reductions in distal femur bone formation (263% vs wild-
type littermates) [26]. Taken together, these data suggest opposing
roles of beta1AR and beta2AR on osteoblasts, and that, when
activated, beta2AR inhibit osteoblast activity, whereas signaling
via beta1AR promotes bone formation.
Administration of b-2 adrenergic agonists results in significant
and deleterious modifications to cancellous bone microarchitec-
ture. Both salbutamol and clenbuterol treatment significantly
reduces metaphyseal bone volume by reducing Tb.Th and
increasing Tb.Sp, resulting in increased rodlike trabecular
structures [15,16,17]. Trabecular microarchitecture was similarly
affected by concurrent beta2AR administration in OVX rats [18].
Data from our current investigation provide evidence for an
opposing effect of dobutamine treatment in the context of disuse.
Dobutamine administration significantly mitigated unloading
associated reductions in BV/TV by attenuating reduced Tb.Th
Table 2. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb unloading (HU) or ambulatory cage activity
(CC) on metaphyseal bone mass and geometry at the distal femur as measured by ex vivo pQCT scans.
CC HU
VEH DOB VEH DOB
Total BMC (mg) 12.1960.42 12.0360.29 10.1060.25b 10.8760.27a,c
Total Bone Area (mm2) 20.6160.76 20.2560.40 19.1860.61 20.4960.54
Total vBMD (mg/cm3) 593.33611.33 595.20611.58 531.02616.39b 533.32611.26c
Cancellous vBMD (mg/cm3) 329.29615.27 320.25612.12 245.9667.77b 271.8566.50a,c
aHU+DOB vs. HU+VEH (p#0.05); bHU+VEH vs. CC+VEH (p#0.05); cHU+DOB vs. CC+DOB (p#0.05).
doi:10.1371/journal.pone.0106904.t002
Figure 3. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb unloading (HU) or ambulatory cage activity
(CC) on cancellous bone measures of histomorphometry. A: Osteoid Surface (OS/BS). B: Osteoblast Surface (ObS/BS). C: Osteoclast Surface
(OcS/BS). D: Adipocyte Density (N.Ad/Ma.Ar). VEH groups are represented by black bars; DOB groups are represented by striped bars. aHU+DOB vs.
HU+VEH (p#0.05); bHU+VEH vs. CC+VEH (p#0.05); cHU+DOB vs. CC+DOB (p#0.05).
doi:10.1371/journal.pone.0106904.g003
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and Tb.N (Table 1). In contrast to the aforementioned delete-
rious effects of b-2 adrenergic agonists, dobutamine administration
to rodents engaged in normal cage activity did not produce any
significant alterations in cancellous bone microarchitecture.
Reductions in metaphyseal bone mass and structure during
hindlimb unloading have been characterized by immediate
increases in osteocyte and osteoblast apoptosis. Recent data have
demonstrated a significant increase in cancellous osteocyte
apoptosis in unweighted proximal tibiae by day 3 of HU,
persisting for up to 18 days after disuse [12,13,27]. An in vitro
study using isoproterenol, an Adrb agonist (equally stimulating
beta1AR and beta2AR), demonstrated beta-adrenergic stimula-
tion to have anti-apoptotic effects on cultured osteoblasts [14].
Data from our investigation provides further evidence that
beta1AR-signaling protects osteocytes from apoptosis, as dobuta-
mine treatment during unloading inhibited disuse-induced in-
creases in osteocyte apoptosis and reductions in osteocyte number
and frequency in cancellous bone as compared to HU-VEH
rodents (Fig. 6). These data provide preliminary evidence for the
role of beta-1 adrenergic signaling to inhibit apoptosis of
mechano-sensing cancellous osteocytes during disuse.
Genetic mouse models have demonstrated the potentially
unique effects of b-1 and b-2 adrenergic receptors on osteoclasts
and osteoblasts, ultimately affecting cancellous bone mass and
microarchitecture. Beta2AR and beta1AR knock-out (KO) mice
have demonstrated a high and low bone mass phenotype,
respectively, whereas beta1/2AR receptor double-KO mice
exhibit a marked reduction in cancellous BFR vs. wild types
[28,29]. Furthermore, complete deletion of all 3 Adrb receptors
results in a significant reduction in bone formation, although
trabecular microarchitecture and bone volume remain unchanged
[26]. Pierroz and colleagues [29] demonstrated that beta1AR
receptor-deficient mice do not respond to mechanical loading,
whereas beta2AR KO mice and wild-type littermates were found
to respond normally. Taken together, these data suggest that the
higher bone mass phenotype in beta2AR KO mice may be due to
enhanced b-1 adrenergic receptor activity, stimulating bone
formation in the absence of the inhibitory effects of b-2 adrenergic
receptors on osteoblasts. Our results are in agreement with these
Figure 4. Effects of dobutamine (DOB) or vehicle (VEH)
administration during hindlimb unloading (HU) or ambulatory
cage activity (CC) on cancellous bone bone cell activity and
marrow adipocyte proliferation. (Top Row) Representative micro-
graphs of osteoblasts (von Kossa and tetrachrome stain; 6400
magnification), (Middle Row) marrow adipocytes (x200 magnification),
and (Bottom Row) fluorochrome labeling (calcein, 2006) on the surface
of cancellous bone at the distal femur. Note the increased number of
osteoblasts (black arrows, top row) and greater osteoid surface (below
osteoblasts) in the HU+DOB group vs. HU+VEH. Also, note the increased
number of marrow adipocytes (red arrows, middle row) in the HU+VEH
group. The increased number of osteoblasts noted in the von Kossa and
tetrachrome stained slides from HU+DOB samples correlated with
extensive flurochrome labeling and large interlabel width (bottom row).
doi:10.1371/journal.pone.0106904.g004
Figure 5. Effects of dobutamine (DOB) or vehicle (VEH)
administration during hindlimb unloading (HU) or ambulatory
cage activity (CC) cancellous bone dynamic histomorphometry
analyses measured at the distal femur. A: Mineralizing Surface
(%MS/BS). B: Mineral Apposition Rate (MAR). C: Bone Formation Rate
(BFR). VEH groups are represented by black bars; DOB groups are
represented by striped bars. aHU+DOB vs. HU+VEH (p#0.05); bHU+VEH
vs. CC+VEH (p#0.05); cHU+DOB vs. CC+DOB (p#0.05).
doi:10.1371/journal.pone.0106904.g005
b-1 Agonist Inhibition of Osteocyte Apoptosis during Disuse
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e106904
genetic mouse studies, demonstrating distinct, opposing effects of
beta1AR and beta2AR on bone remodeling, especially during a
period of disuse. Delineating the effects of beta1AR stimulation on
disuse-sensitive cancellous bone during reduced mechanical
loading is crucial to defining the underlying mechanisms
responsible for bone loss.
One limitation to the current study was the lack of available
serum to determine whether beta1AR treatment mitigated the
usual decline in circulating insulin-like growth factor 1 (IGF-1)
during disuse. Complicating this picture is the fact that hindlimb
unloading induces resistance to IGF-1 by inhibiting activation of
the IGF-1 signaling pathways [30,31]. Furthermore, serum IGF-1
is lower in beta1AR and beta2AR knock-out mice vs. wild-type,
and femur BMD and cancellous BV/TV in beta1/2AR KO mice
has been associated with reduced systemic IGF-1 [29]. We
speculate that IGF-1 signaling likely played a critical role in bone’s
response to beta1AR agonist treatment during disuse. A second
limitation is the lack of immunohistochemistry analyses of
beta1AR and beta2AR expression in osteoblasts and osteoclasts
within weightbearing bone in this study. Previous investigations
have determined that human periosteal and rodent osteoblasts
express both beta1AR and beta1AR, although the majority of
research demonstrates beta2AR to be the primary receptor
expressed in osteoblasts [25,32,33,34,35]. However, to our
knowledge it has yet to be determined whether beta1AR are
expressed in osteocytes. Understanding how disuse may alter
expression of these receptors in bone cells, as well as the
mechanisms responsible for the skeletal effects of beta1AR agonist
stimulation, is a critical next step in this line of research.
In conclusion, these data contribute significant evidence to the
importance of b-1 adrenergic receptor agonist signaling in bone to
mitigate disuse-induced increases in bone fragility and reductions
in bone mass. Specifically, treatment with beta1AR agonist during
unloading significantly impacted metaphyseal bone and inhibited
associated increases in osteocyte apoptosis. These data further
define the role that b-adrenergic receptors have in mediating
bone’s response to periods of disuse or unloading.
Acknowledgments
The authors gratefully acknowledge the technical assistance of Dr.
Elizabeth Greene and Ms. Sara Luna, and Dr. Florence Lima for her
review of this manuscript. We also thank the Texas A&M University
Comparative Medicine Program technical and veterinary staff for their
high quality of animal care.
The views, opinions, and findings contained herein are those of the
author and do not necessarily reflect official policy or positions of the
Armed Forces Radiobiology Research Institute, the Uniformed Services
University of the Health Sciences, the Department of the Navy, the
Department of Defense, nor the United States Government.
Author Contributions
Conceived and designed the experiments: JMS SAB. Performed the
experiments: JMS SNS. Analyzed the data: JMS SNS MRA. Contributed
reagents/materials/analysis tools: JMS SNS MRA SAB. Contributed to
the writing of the manuscript: JMS SNS MRA SAB.
References
1. (2002) America’s bone health: the state of osteoporosis and low bone mass in our
nation. Washington, DC: National Osteoporosis Foundation.
2. Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, et al. (2001) The
influence of osteoporotic fractures on health-related quality of life in community-
dwelling men and women across Canada. Osteoporos Int 12: 903–908.
3. Cooper C (1997) The crippling consequences of fractures and their impact on
quality of life. Am J Med 103: 12S–17S; discussion 17S–19S.
4. Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, et al. (2000)
Prevalent vertebral deformities predict mortality and hospitalization in older
women with low bone mass. Fracture Intervention Trial Research Group. J Am
Geriatr Soc 48: 241–249.
5. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, et al. (2000) Health-related
quality of life in postmenopausal women with low BMD with or without
prevalent vertebral fractures. J Bone Miner Res 15: 1384–1392.
6. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, et al. (2007)
Incidence and economic burden of osteoporosis-related fractures in the United
States, 2005–2025. J Bone Miner Res 22: 465–475.
7. Ehrlich PJ, Lanyon LE (2002) Mechanical strain and bone cell function: a
review. Osteoporos Int 13: 688–700.
8. Allen MR, Bloomfield SA (2003) Hindlimb unloading has a greater effect on
cortical compared with cancellous bone in mature female rats. J Appl Physiol 94:
642–650.
9. Baek K, Barlow AA, Allen MR, Bloomfield SA (2008) Food restriction and
simulated microgravity: effects on bone and serum leptin. J Appl Physiol 104:
1086–1093.
10. Bloomfield SA, Allen MR, Hogan HA, Delp MD (2002) Site- and compartment-
specific changes in bone with hindlimb unloading in mature adult rats. Bone 31:
149–157.
11. Turner RT, Lotinun S, Hefferan TE, Morey-Holton E (2006) Disuse in adult
male rats attenuates the bone anabolic response to a therapeutic dose of
parathyroid hormone. J Appl Physiol 101: 881–886.
12. Aguirre JI, Plotkin LI, Stewart SA, Weinstein RS, Parfitt AM, et al. (2006)
Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast
recruitment and bone loss. J Bone Miner Res 21: 605–615.
13. Basso N, Heersche JN (2006) Effects of hind limb unloading and reloading on
nitric oxide synthase expression and apoptosis of osteocytes and chondrocytes.
Bone 39: 807–814.
14. Chen X, Song IH, Dennis JE, Greenfield EM (2007) Endogenous PKI gamma
limits the duration of the anti-apoptotic effects of PTH and beta-adrenergic
agonists in osteoblasts. J Bone Miner Res 22: 656–664.
Figure 6. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb unloading (HU) or ambulatory cage activity
(CC) on cancellous bone osteocytes measured at the distal femur. A: TUNEL+ osteocytes (%). B: Total number of osteocytic lacunae (N.Ot/
B.Ar). C: Osteocyte occupancy frequency (%). VEH groups are represented by black bars; DOB groups are represented by striped bars. aHU+DOB vs.
HU+VEH (p#0.05); bHU+VEH vs. CC+VEH (p#0.05); cHU+DOB vs. CC+DOB (p#0.05).
doi:10.1371/journal.pone.0106904.g006
b-1 Agonist Inhibition of Osteocyte Apoptosis during Disuse
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e106904
15. Bonnet N, Benhamou CL, Beaupied H, Laroche N, Vico L, et al. (2007) Doping
dose of salbutamol and exercise: deleterious effect on cancellous and cortical
bones in adult rats. J Appl Physiol 102: 1502–1509.
16. Bonnet N, Benhamou CL, Brunet-Imbault B, Arlettaz A, Horcajada MN, et al.
(2005) Severe bone alterations under beta2 agonist treatments: bone mass,
microarchitecture and strength analyses in female rats. Bone 37: 622–633.
17. Bonnet N, Brunet-Imbault B, Arlettaz A, Horcajada MN, Collomp K, et al.
(2005) Alteration of trabecular bone under chronic beta2 agonists treatment.
Med Sci Sports Exerc 37: 1493–1501.
18. Bonnet N, Laroche N, Beaupied H, Vico L, Dolleans E, et al. (2007) Doping
dose of salbutamol and exercise training: impact on the skeleton of
ovariectomized rats. J Appl Physiol 103: 524–533.
19. Bloomfield SA, Girten BE, Weisbrode SE (1997) Effects of vigorous exercise
training and beta-agonist administration on bone response to hindlimb
suspension. J Appl Physiol 83: 172–178.
20. Swift JM, Hogan HA, Bloomfield SA (2013) Beta-1 adrenergic agonist mitigates
unloading-induced bone loss by maintaining formation. Med Sci Sports Exerc
45: 1665–1673.
21. Swift JM, Nilsson MI, Hogan HA, Sumner LR, Bloomfield SA (2010) Simulated
resistance training during hindlimb unloading abolishes disuse bone loss and
maintains muscle strength. J Bone Miner Res 25: 564–574.
22. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. (1987)
Bone histomorphometry: standardization of nomenclature, symbols, and units.
Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone
Miner Res 2: 595–610.
23. Swift JM, Swift SN, Nilsson MI, Hogan HA, Bouse SD, et al. (2011) Cancellous
bone formation response to simulated resistance training during disuse is blunted
by concurrent alendronate treatment. J Bone Miner Res 26: 2140–2150.
24. Kondo H, Nifuji A, Takeda S, Ezura Y, Rittling SR, et al. (2005) Unloading
induces osteoblastic cell suppression and osteoclastic cell activation to lead to
bone loss via sympathetic nervous system. J Biol Chem 280: 30192–30200.
25. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, et al. (2002) Leptin
regulates bone formation via the sympathetic nervous system. Cell 111: 305–
317.
26. Bouxsein ML, Devlin MJ, Glatt V, Dhillon H, Pierroz DD, et al. (2009) Mice
lacking beta-adrenergic receptors have increased bone mass but are not
protected from deleterious skeletal effects of ovariectomy. Endocrinology 150:
144–152.
27. Dufour C, Holy X, Marie PJ (2007) Skeletal unloading induces osteoblast
apoptosis and targets alpha5beta1-PI3K-Bcl-2 signaling in rat bone. Exp Cell
Res 313: 394–403.
28. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, et al. (2005) Leptin
regulation of bone resorption by the sympathetic nervous system and CART.
Nature 434: 514–520.
29. Pierroz DD, Bonnet N, Bianchi EN, Bouxsein ML, Baldock PA, et al. (2012)
Deletion of beta-adrenergic receptor 1, 2, or both leads to different bone
phenotypes and response to mechanical stimulation. J Bone Miner Res 27:
1252–1262.
30. Sakata T, Halloran BP, Elalieh HZ, Munson SJ, Rudner L, et al. (2003) Skeletal
unloading induces resistance to insulin-like growth factor I on bone formation.
Bone 32: 669–680.
31. Sakata T, Wang Y, Halloran BP, Elalieh HZ, Cao J, et al. (2004) Skeletal
unloading induces resistance to insulin-like growth factor-I (IGF-I) by inhibiting
activation of the IGF-I signaling pathways. J Bone Miner Res 19: 436–446.
32. Kellenberger S, Muller K, Richener H, Bilbe G (1998) Formoterol and
isoproterenol induce c-fos gene expression in osteoblast-like cells by activating
beta2-adrenergic receptors. Bone 22: 471–478.
33. Kondo H, Takeuchi S, Togari A (2013) beta-Adrenergic signaling stimulates
osteoclastogenesis via reactive oxygen species. Am J Physiol Endocrinol Metab
304: E507–515.
34. Moore RE, Smith CK 2nd, Bailey CS, Voelkel EF, Tashjian AH, Jr. (1993)
Characterization of beta-adrenergic receptors on rat and human osteoblast-like
cells and demonstration that beta-receptor agonists can stimulate bone
resorption in organ culture. Bone Miner 23: 301–315.
35. Togari A, Arai M, Mizutani S, Koshihara Y, Nagatsu T (1997) Expression of
mRNAs for neuropeptide receptors and beta-adrenergic receptors in human
osteoblasts and human osteogenic sarcoma cells. Neurosci Lett 233: 125–128.
b-1 Agonist Inhibition of Osteocyte Apoptosis during Disuse
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e106904
